Effects of Extended-Release Dipyridamole In Vitro on Thrombin Indices Measured by Calibrated Automated Thrombography in Poststroke Survivors
暂无分享,去创建一个
[1] R. Liu,et al. Thrombin Regulates the Metastatic Potential of Human Rhabdomyosarcoma Cells: Distinct Role of PAR1 and PAR3 Signaling , 2010, Molecular Cancer Research.
[2] T. Obisesan,et al. Thrombin and exercise similarly influence expression of cell cycle genes in cultured putative endothelial progenitor cells. , 2010, Journal of applied physiology.
[3] Wen-Bin Wu,et al. Thrombin induces cyclooxygenase‐2 expression and prostaglandin E2 release via PAR1 activation and ERK1/2‐ and p38 MAPK‐dependent pathway in murine macrophages , 2009, Journal of cellular biochemistry.
[4] S. Kwon,et al. Inflammatory and hemostatic biomarkers associated with early recurrent ischemic lesions in acute ischemic stroke. , 2009, Stroke.
[5] Bernard Pirotte,et al. Is thrombin generation the new rapid, reliable and relevant pharmacological tool for the development of anticoagulant drugs? , 2009, Pharmacological research.
[6] J. Gummert,et al. Correlations between platelet-derived microvesicles and thrombin generation in patients with coronary artery disease , 2008, Platelets.
[7] J. Freedman,et al. Redox State of Dipyridamole is a Critical Determinant for Its Beneficial Antioxidant and Antiinflammatory Effects , 2007, Journal of cardiovascular pharmacology.
[8] Alisa S Wolberg,et al. Thrombin generation and fibrin clot structure. , 2007, Blood reviews.
[9] C. Schmidt. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT) : randomized controlled trial , 2006 .
[10] A. Algra,et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial , 2006, The Lancet.
[11] W. Bode,et al. Structure and interaction modes of thrombin. , 2006, Blood cells, molecules & diseases.
[12] D. Atar,et al. Dipyridamole Decreases Protease-Activated Receptor and Annexin-V Binding on Platelets of Poststroke Patients with Aspirin Nonresponsiveness , 2006, Cerebrovascular Diseases.
[13] T. Baglin,et al. Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition , 2004, Journal of thrombosis and haemostasis : JTH.
[14] R. Sacco,et al. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.
[15] S. Béguin,et al. Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time , 2004, Journal of thrombosis and haemostasis : JTH.
[16] D. Sane,et al. Risk of bleeding complications with antiplatelet agents: Meta‐analysis of 338,191 patients enrolled in 50 randomized controlled trials , 2004, American journal of hematology.
[17] H. Coenraad Hemker,et al. Calibrated Automated Thrombin Generation Measurement in Clotting Plasma , 2003, Pathophysiology of Haemostasis and Thrombosis.
[18] S. Béguin,et al. The Calibrated Automated Thrombogram (CAT): a universal routine test for hyper- and hypocoagulability , 2002, Pathophysiology of Haemostasis and Thrombosis.
[19] Mayo Clinic,et al. Anticoagulants and antiplatelet agents in acute ischemic stroke: Report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a Division of the American Heart Association) , 2002, Stroke.
[20] J. Meschia,et al. Anticoagulants and Antiplatelet Agents in Acute Ischemic Stroke: Report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a Division of the American Heart Association) , 2002, Neurology.
[21] P. Amarenco,et al. Antithrombotic and thrombolytic therapy for ischemic stroke. , 1998, Chest.
[22] H. Diener,et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke 1 1 ESPS-2 Writing Committee , 1996, Journal of the Neurological Sciences.
[23] T. Lindhout,et al. The Anticoagulant Mechanism of Action of Recombinant Hirudin (CGP 39393) in Plasma , 1990, Thrombosis and Haemostasis.
[24] A. Ordinas,et al. Inhibitory effects of dipyridamole on growth, nucleoside incorporation, and platelet-activating capability in the U87MG and SKNMC human tumor cell lines. , 1985, Cancer research.
[25] V. Gurewich,et al. Inhibition of intravascular fibrin deposition by dipyridamole in experimental animals. , 1975, Blood.
[26] W. Muntean,et al. The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT. , 2007, Thrombosis research.
[27] R. De Cristofaro,et al. Thrombin Domains: Structure, Function and Interaction with Platelet Receptors , 2004, Journal of Thrombosis and Thrombolysis.
[28] M. Wolzt,et al. The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma. , 2004, Thrombosis research.
[29] A. Lowenthal. The European Stroke Prevention Study , 1988, Acta neurologica Belgica.